The immunogenicity of intradermal influenza vaccination in COPD patients |
| |
Authors: | Benjamas Chuaychoo Phunsup Wongsurakiat Arth Nana Uraiwan Kositanont Khun Nanta Maranetra |
| |
Institution: | 1. Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Pranok Road, BangkokNoi, Bangkok 10700, Thailand;2. Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand |
| |
Abstract: | We evaluated the immunogenicity of a reduced-dose intradermal trivalent, inactivated, split-virion seasonal influenza vaccine compared to that of a conventional intramuscular vaccination in chronic obstructive pulmonary disease (COPD) patients. One hundred and fifty-six COPD patients randomly received either 0.2 ml (6 μg hemagglutinin (HA) per strain) split into two-site intradermal (ID) injections or a single 0.5 ml (15 μg HA per strain) intramuscular (IM) injection. Geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates at 4 weeks post-vaccination in the ID group were less than those in the IM group. Only the seroconversion factor to influenza B in the ID group was statistically less than in the IM group (18.8 in the ID group, n = 81 versus 37.3 in the IM group, n = 75, p = 0.045). Nevertheless, each strain of the ID vaccination met all the Committee for Proprietary Medicinal Products (CPMP) criteria. Seroprotection rates were above 60% throughout the year in influenza A (H3N2), for at least 6 months in influenza A (H1N1) and at least 4 weeks in influenza B in both ID and IM groups. The reduced-dose intradermal vaccination may be considered for use in COPD patients in a vaccine shortage situation. |
| |
Keywords: | Intradermal Influenza vaccine COPD |
本文献已被 ScienceDirect 等数据库收录! |
|